{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-008039","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.193310+00:00","generated_at":"2026-06-27T03:00:35.761766+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xenon reports FY2021 net loss $78.9M; XEN1101 Phase 3 expected H2 2022","bullets":["Net loss $78.9M vs $28.8M in 2020; revenue $18.4M vs $32.2M.","Cash $551.8M (Dec 31, 2021) vs $177.0M; expects funding into at least 2024.","XEN1101 Phase 2b met primary endpoint; end-of-Phase 2 FDA meeting Q2 2022; Phase 3 start H2 2022.","XEN496 Phase 3 EPIK trial for KCNQ2-DEE enrolling; completion expected H1 2023.","Partner Neurocrine Phase 2 for NBI-921352 ongoing; Pacira Phase 1b for PCRX301 data expected Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-008039","json":"https://secwatch.observer/filing/0001564590-22-008039.json","markdown":"https://secwatch.observer/filing/0001564590-22-008039.md","text":"https://secwatch.observer/filing/0001564590-22-008039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022008039/0001564590-22-008039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022008039/xene-8k_20220301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:00:35.761766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}